← Back to home

E1 UBIQUTIN-ACTIVATING ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC SYNDROME

Clinical trials for E1 UBIQUTIN-ACTIVATING ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC SYNDROME explained in plain language.

Never miss a new study

Get alerted when new E1 UBIQUTIN-ACTIVATING ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC SYNDROME trials appear

Sign up with your email to follow new studies for E1 UBIQUTIN-ACTIVATING ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Experimental drug pacritinib takes aim at rare inflammatory VEXAS syndrome

Disease control Recruiting now

This phase 1 trial tests the safety and tolerability of pacritinib, a pill that blocks JAK2 and IRAK1, in people with VEXAS syndrome—a rare, severe autoinflammatory disorder caused by a UBA1 gene mutation. Up to 15 participants will take pacritinib daily for up to 12 cycles, star…

Matched conditions: E1 UBIQUTIN-ACTIVATING ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC SYNDROME

Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control

Last updated Jul 17, 2026 00:00 UTC

E1 UBIQUTIN-ACTIVATING ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC SYNDROME

Get alerted when new E1 UBIQUTIN-ACTIVATING ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC SYNDROME trials appear

Experimental drug pacritinib takes aim at rare inflammatory VEXAS syndrome